Key result
Dipyrone is linked to reduced low-dose aspirin efficacy for inhibiting platelet aggregation in CABG patients.
Why the study?
Low-dose aspirin failed to inhibit platelet aggregation in patients undergoing coronary bypass grafting, suggesting a drug interaction with nonopioid analgesics that may increase thrombotic risk.
Does dipyrone (metamizol) inhibit the antiplatelet effects of low-dose aspirin in patients undergoing coronary bypass grafting?
Observational
Does dipyrone (metamizol) inhibit the antiplatelet effects of low-dose aspirin in patients undergoing coronary bypass grafting?
Dipyrone (metamizol) interacts with low-dose aspirin to prevent its antiplatelet effects, potentially increasing the risk of thrombotic events in post-CABG patients.
Dipyrone may blunt aspirin's antiplatelet effect after CABG; hypothesis-generating for graft occlusion risk and requires confirmation.
In patients undergoing coronary bypass grafting, we noticed that low-dose aspirin failed to inhibit platelet aggregation, potentially elevating the risk of thrombotic bypass occlusion. This "high on-treatment platelet reactivity" was reproducible in vitro and could be transferred with patient plasma or urine to aspirin-sensitive donor platelets, suggesting a drug/drug interaction. Loss of aspirin efficacy was associated with analgesia by dipyrone (metamizol) and initiated further study of the interaction between aspirin and other nonopioid analgesics.
No takes yet. Share an insight, caveat, or question.
Hohlfeld et al. (2014) conducted an observational in Coronary bypass grafting. Dipyrone (metamizol) was evaluated on Platelet aggregation / high on-treatment platelet reactivity. Dipyrone (metamizol) exposure was associated with a loss of low-dose aspirin efficacy in inhibiting platelet aggregation among patients undergoing coronary bypass grafting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: